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Abstract
Introduction: Acute lung injury (ALI) after cardiac surgery is associated with a high postoperative morbidity and
mortality, but few predictors are known for the occurrence of the complication. This study evaluated whether
elevated plasma levels of soluble receptor for advanced glycation end products (sRAGE) and S100A12 reflected
impaired lung function in infants and young children after cardiac surgery necessitating cardiopulmonary bypass
(CPB).
Methods: Consecutive children younger than 3 years after cardiac surgery were prospectively enrolled and
assigned to ALI and non-ALI groups, according to the American-European Consensus Criteria. Plasma
concentrations of sRAGE and S100A12 were measured at baseline, before, and immediately after CPB, as well as 1
hour, 12 hours, and 24 hours after operation.
Results: Fifty-eight patients were enrolled and 16 (27.6%) developed postoperative ALI. Plasma sRAGE and S100A12
levels increased immediately after CPB and remained significantly higher in the ALI group even 24 hour after
operation (P < 0.01). In addition, a one-way MANOVA revealed that the overall sRAGE and S100A12 levels were
higher in the ALI group than in the non-ALI group immediately after CPB (P < 0.001). The multivariate logistic
regression analysis showed that the plasma sRAGE level immediately after CPB was an independent predictor for
postoperative ALI (OR, 1.088; 95% CI, 1.011 to 1.171; P = 0.025). Increased sRAGE and S100A12 levels immediately
after CPB were significantly correlated with a lower PaO2/FiO2 ratio (P < 0.01) and higher radiographic lung-injury
score (P < 0.01), as well as longer mechanical ventilation time (sRAGEN: r = 0.405; P = 0.002; S100A12N: r = 0.322;
P = 0.014), longer surgical intensive care unit stay (sRAGEN: r = 0.421; P = 0.001; S100A12N: r = 0.365; P = 0.005) and
hospital stay (sRAGEN: r = 0.329; P = 0.012; S100A12N: r = 0.471; P = 0.001).
Conclusions: Elevated sRAGE and S100A12 levels correlate with impaired lung function, and sRAGE is a useful early
biomarker of ALI in infants and young children undergoing cardiac surgery.
Introduction
Postoperative lung injury may occur in 12% to 50% of
patients undergoing cardiac surgery necessitating cardio-
pulmonary bypass (CPB) [1-4], and up to 20% of the
patients need ventilation for more than 48 hours [5].
Acute respiratory distress syndrome (ARDS) occurs in 2%
of these cases, resulting a mortality of 15% to 50% [3,4].
Children are more prone to acute lung injury (ALI) under
the detrimental stimulation during cardiac surgery with
CPB [6-8]. ALI/ARDS after CPB often leads to a pro-
longed length of hospital stay and increased therapeutic
costs. Therefore, developing certain predictive biomarker
for CPB-related ALI/ARDS in infants and young children
undergoing cardiac surgery would be of great help for
early diagnosis and efficient therapeutic decision making.
The receptor for advanced glycation end products
(RAGE) is a member of the immunoglobulin superfamily
that acts as a multiligand receptor and progression factor
in propagating the inflammatory response [9,10]. RAGE
is expressed at a high level in the basal surface of alveolar
type I cells, and its expression is upregulated under
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inflammatory conditions [9,11,12]. Soluble RAGE
(sRAGE) is the extracellular form of RAGE and is pro-
duced by either cleaving the membrane by proteolysis or
removing the transmembrane region via alternative spli-
cing [12]. Increasing evidence suggests that local and cir-
culating levels of sRAGE are promising as biomarkers of
pulmonary tissue damage. The sRAGE concentration has
been reported to be dramatically higher in pulmonary
edema fluid and plasma from adult patients with ALI/
ARDS, which were caused by sepsis, trauma, or primary
pneumonia [13,14]. Furthermore, increased plasma
sRAGE levels are significantly correlated with the severity
and clinical outcome of ALI/ARDS [15,16].
S100A12 is a member of the S100 family of calcium-
binding proteins, which is a newly identified extracellular
prototypic ligand of RAGE [17,18]. S100A12 expression
may reflect neutrophil activation and contribute to pul-
monary inflammation and endothelial activation via bind-
ing to RAGE [14,18]. Blocking the interaction of S100A12
and RAGE results in improvement of inflammation in
multiple experimental models [18,19]. Wittkowski et al.
[14] found that compared with healthy controls, patients
with ARDS caused by pneumonia or peritonitis had signif-
icantly enhanced S100A12 expression in pulmonary tissue
and higher S100A12 concentrations in bronchoalveolar
lavage fluid.
Plasma sRAGE was recently reported to be a sensitive
and rapid marker of lung distress after elective coronary
artery bypass grafting in a study of 20 adult patients [20].
Additionally, Kikkawa and colleagues [21] found that
sepsis patients who developed postoperative ALI had
higher S100A12 levels compared with controls. Initial
studies are promising. However, it is not clear whether
these findings could extend to younger children under-
going cardiac surgery with CPB.
This pilot study aimed to observe the kinetics of plasma
sRAGE and S100A12 in infants and young children
undergoing cardiac surgery with CPB and to investigate
whether plasma sRAGE and S100A12 levels are asso-




This prospective study was conducted at a university chil-
dren’s hospital located in eastern China. The study proto-
cols were approved by the hospital ethics committee
(Medical Ethical Committee of the Children’s Hospital of
Zhejiang University), and informed consents were signed
by supervisors of the patients. Children who were younger
than 3 years and scheduled for cardiac surgery for conge-
nital heart disease (CHD) were consecutively enrolled. The
included patients had stable clinical conditions for at least
2 months. Patients were excluded if they were premature,
had abnormal liver or renal function, had major chromo-
somal abnormalities, showed pulmonary inflammation
before the surgery, had pulmonary edema due to cardiac
dysfunction, needed extracorporeal membrane oxygena-
tion support after the operation, died because of cardiac
dysfunction, or refused to participate in the study.
Data collection and definitions
During the surgical procedure, all patients underwent
routine hemodynamic and blood gas surveillance.
Anesthesia, the CPB procedure, and weaning from
mechanical ventilation (MV) in the surgical Intensive
Care Unit (ICU) were all performed by using standard
protocols, as shown in additional material in detail
[Additional file 1].
Demographic and preoperative data were collected,
including the patient’s gender, age, weight, pulse oxime-
try saturation (SpO2), Risk Adjusted Classification for
Congenital Heart Surgery (RACHS-1), ultrafiltrate
volume, CPB time and operation time, duration of MV,
and the ratio of fraction of inspired oxygen to oxygen
pressure (PaO2/FiO2). A bedside chest radiograph was
taken every day after surgery. A structured tutorial was
used to establish consensus in the interpretation of radio-
graphs for radiographic lung-injury scores (LISs) [16,22].
Echocardiography was performed routinely to evaluate
the cardiac function after surgery and at any time if
necessary. The left ventricular function was evaluated by
the ejection fraction (EF). The North American-European
Consensus Criteria were used to categorize the patients
into the ALI group and non-ALI group. In brief, this cri-
terion includes the acute onset of bilateral alveolar infil-
trates seen on a chest radiograph, a PaO2/FiO2 ratio <
300, and the absence of cardiogenic pulmonary edema
(CPE) [23]. CPE was identified when the pulmonary
arterial occlusion pressure was > 18 mm Hg or by the
presence of at least two of the following: central venous
pressure > 14 mm Hg, left ventricular EF < 45%, systemic
hypertension, or volume overload. Patients with CPE
were excluded; CPE was diagnosed by two independent
attending cardiac intensivists, who were blinded to the
group of ALI patients. In addition, the both groups were
followed up for ICU length of stay (LOS) and hospital
LOS.
Determination of sRAGE and S100A12 in plasma
For each patient, 2 ml of fresh blood was drawn into a
vacuum tube containing EDTA at the following time
points: before operation, before CPB, after CPB, 1 hour, 12
hours, and 24 hours after operation. After being centri-
fuged at 3,000 rpm for 15 minutes at 4°C, the plasma was
divided into aliquots and frozen at -80°C until assay.
sRAGE and S100A12 levels were measured by using
the commercially available ELISA kits (sRAGE, R&D
Liu et al. Critical Care 2012, 16:R91
http://ccforum.com/content/16/3/R91
Page 2 of 10
Systems, Minneapolis, MN, USA; S100A12, Cirulex;
Cyclex Co. Ltd, Nagano, Japan), according to the manu-
facturer’s instructions. The plasma total protein levels
were determined with an autobiochemistry analyzer and
used for sRAGE and S100A12 normalization (sRAGEN,
sRAGE normalized for total protein; S100A12N, S100A12
normalized for total protein). Laboratory staffs were
blinded to the ALI patients, and investigators involved in
the interpretation of ALI were blinded to sRAGE and
S100A12 levels.
Statistical analysis
Continuous data were tested for normal distribution with
the one-sample Kolmogorov-Smirnov test. Variables
were presented as mean values and standard deviations if
normally distributed, and otherwise, as median values
(interquartile range). The Student t test and Mann-Whit-
ney U test were used to determine the significance of
variable differences between the two groups. The c2 test
or Fisher Exact test were used to compare categorical
data as appropriate. A multivariate analysis of variance
procedure (MANOVA) was used to assess whether a sig-
nificant difference remained in the overall assessment of
sRAGE and S100A12 levels between the two groups. A
Pearson or Spearman correlation test was performed to
determine the correlation between biomarker (sRAGE
and S100A12) data and clinical parameters (CPB time,
PaO2/FiO2 ratio, MV time, and ICU and hospital LOS).
Receiver operating characteristic curve (ROC) was com-
puted, and area under the curve (AUC) was used to eval-
uate how well the biomarkers diagnose ALI. A stepwise
logistic regression model was used to determine the inde-
pendent risk factor for ALI after CPB. The multivariate
variables included age, weight, sex, CPB time, operation
time, and the concentration of sRAGEN and S100A12N
immediately after CPB. These variables were then
entered into a stepwise multiple linear regression analysis
to determine the factors significantly associated with the
PaO2/FiO2 ratio within the first 2 days. A P value < 0.05
was considered statistically significant. All statistical
analyses were performed by using SPSS (SPSS 16.0 for
Windows; SPSS, Chicago, IL, USA).
Results
Study population
From May 1 to June 30, 2011, of the 71 consecutive
patients younger than 3 years who underwent cardiac
surgery, 58 (81.7%) fulfilled the inclusion criteria, which
included 27 (46.6%) infants. Thirteen patients were
excluded for the following reasons: pneumonia before
surgery (eight patients), liver insufficiency (one patient),
prematurity (two patients), receiving cardiopulmonary
resuscitation owing to low-cardiac-output syndrome (one
patient), and absence of written informed consent (one
patient). Finally, among the 58 patients, 16 (27.6%) devel-
oped ALI. The characteristics and cardiac-lesion types of
the enrolled patients are shown in Tables 1 and 2,
respectively.
Perioperative sRAGE and S100A12 concentrations
Plasma sRAGE and S100A12 concentrations are shown
in Table 3, both as absolute values (picograms per milli-
liter) and normalized values (picograms per milligram
total protein). The latter values were needed because
total plasma protein concentration decreased dramati-
cally during CPB (P < 0.001). Plasma levels of sRAGE








Sex male n (%) 28 (48.3%) 10 (62.5%) 18 (42.9%) 0.181
Age (months) 12.2 ± 5.8 6.7 ± 4.0 14.3 ± 5.0 < 0.001
Weight (kg) 8 ± 2 6.3 ± 1.9 8.6 ± 1.6 < 0.001
RACHS-1 0.409
≤2 49 12 37
≥3 9 4 5
SPO2 (%) 97 (95-98) 95 (90-97) 98 (96-98) 0.002
Operation time (minutes) 131.9 ± 30.4 148.7 ± 20.4 125.4 ± 31.3 0.008
CPB time (minutes) 65.5 ± 22.8 81.1 ± 15.82 59.5 ± 22.4 0.001
UFV (ml) 328.1 ± 128.2 365.6 ± 142.4 313.81 ± 121.1 0.171
Nosocomial pneumonias 9 (15.5%) 4 (25%) 5 (11.9%) 0.409
MV time (hours) 7 (4.8-26.2) 27 (26.2-34.4) 5.2 (4.3-11.8) < 0.001
SICU LOS (days) 4.44 ± 2.8 7.6 ± 2.9 3.4 ± 1.6 < 0.001
Hospital LOS (days) 20 ± 7.8 26.8 ± 9.4 17.4 ± 5.2 < 0.001
Data are presented as number of patients (%), median (interquartile range), or counts, as appropriate. ALI, acute lung injury; CPB, cardiopulmonary bypass; LOS,
length of stay; MV, mechanical ventilation; RACHS-1, Risk Adjusted Classification for Congenital Heart Surgery; SICU, surgery intensive care unit; SPO2, oxygen
saturation; UFV, ultrafiltered volume removal.
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and S100A12 increased significantly immediately after
CPB (P < 0.001), and the elevated levels were correlated
with the CPB time (Figure 1; sRAGE: r = 0.303; P =
0.021; sRAGEN: r = 0.305; P = 0.02; S100A12: r = 0.371;
P = 0.004; S100A12N: r = 0.376; P = 0.004). Therefore,
the normalized values (sRAGEN and S100A12N, respec-
tively) immediately after CPB were used for subsequent
analysis. Twenty-four hours after operation, the levels of
sRAGE decreased lower than the baseline levels (P <
0.05), whereas S100A12 levels remained higher (P <
0.001).
Plasma sRAGE as a predictor for acute lung injury
The post-CPB ALI development not only was associated
with age, weight, operation time, and CPB time (P <
0.01) (Table 1), but also was significantly associated with
the levels of sRAGE and S100A12 immediately after
CPB (Figure 2; P < 0.01). In addition, the levels of
sRAGE and S100A12 were kept higher in the ALI group
than those in non-ALI group at 24 hours after operation
(Figure 2; P < 0.01). The one-way MANOVA analysis
revealed that ALI patients had significantly increased
overall biomarkers of sRAGE and S100A12, as com-
pared with the non-ALI ones, both immediately after
CPB and 24 hours after operation (F = 29.06; P < 0.001
and F = 11.72; P < 0.001, respectively).
In the ROC analysis, the AUC of sRAGEN and
S100A12N levels immediately after CPB for ALI were
0.775 (95% CI, 0.626 to 0.924) and 0.714 (95% CI, 0.539
to 0.889), respectively. At a cutoff value of 54 pg/mg,
sRAGEN had a sensitivity of 70% and a specificity of 91%
for diagnosis of ALI after CPB, whereas at a cutoff of
4,326.5 pg/mg, S100A12N had a sensitivity of 58% and a
specificity of 100% (Figure 3). The logistic regression ana-
lysis, which included age, weight, sex, operation time, and
CPB time, as well as S100A12N and sRAGEN levels
immediately after CPB, revealed that the independent
risk factors for the occurrence of ALI were sRAGEN (OR,
1.088; 95% CI, 1.011 to 1.171; P = 0.025), age (OR, 0.681;
95% CI, 0.528 to 0.879; P = 0.003), and CPB time (OR,
1.070; 95% CI, 1.008 to 1.136; P = 0.026).
Plasma sRAGE and S100A12 predict the severity of acute
lung injury and clinical outcomes
Higher levels of plasma sRAGEN and S100A12N immedi-
ately after CPB were significantly associated with more-
severe ALI, as reflected by the measurement of pulmon-
ary physiology, including the PaO2/FiO2 ratio on the first
2 days (Figure 4A and 4B for the first day; sRAGEN: r =
-0.404; P = 0.002; S100A12N: r = -0.56; P < 0.001; Figure
4C and 4D for the second day: sRAGEN: r = -0.448; P <
0.001; S100A12N: r = -0.489; P < 0.001), as well as radio-
graphic LIS (Figure 4E and 4F; P < 0.01). After adjusting
for age, weight, sex, operation time, and CPB time in a
multiple linear regression model, we found that sRAGEN
but not S100A12N levels immediately after CPB were
independently associated with the PaO2/FiO2 ratio on
the second day (B = -2.153; 95% CI, -0.559 to -3.747;
Table 2 Cardiac lesion types in the study cohort
Type of lesion Study cohort ALI Non-ALI
VSD plus ASD 13 3 (18.8) 10 (23.8)
VSD 14 2 (12.5) 12 (28.6)
ASD 4 0 (0) 4 (9.5)
TOF 6 2 (12.5) 4 (9.5)
TAPVC plus ASD or VSD 5 2 (12.5) 3 (7.1)
Atrioventricular canal defect 7 3 (18.8) 4 (9.5)
DORV plus PS 4 2 (12.5) 2 (4.8)
PA plus VSD plus PDA 5 2 (12.5) 3 (7.1)
Total 58 16 42
Data are presented as counts (%). ASD, atrial septal defect; DORV, double-
outlet right ventricle; PS, pulmonary stenosis; TAPVC, total anomalous
pulmonary venous connection; TOF, tetralogy of Fallot; VSD, ventricular septal
defect.
Table 3 Perioperative gas-exchange parameters and plasma sRAGE and S100A12 data
Variables Before
surgery






PaO2 (mm Hg) 191.5 ± 60.5 185.3 ± 77.2 156.2 ± 40.4 146.2 ± 39.3 111.4 ± 20.8
PaCO2 (mm Hg) 34.4 ± 4.5 40.5 ± 7.4 36.6 ± 5.7 37.1 ± 4.6 37.2 ± 5.2
FiO2 Room air 0.47 ± 0.9 0.60 ± 0.19 0.50 ± 0.04 0.45 ± 0.1 0.33 ± 0.15
Total protein (g/L) 63.74 ± 4.76 51.99 ± 4.05 49.76 ± 4.78a 51 ± 4.35b 55.4 ± 5.47c 55.18 ± 6.35d, e




2,073.91 ± 911.82a 1,587.15 ± 657.35b, f 753.74 ± 460.27c, g 508.38 ± 270.03d, e
sRAGEN (pg/mg) 12.91 ± 4.3 20 ± 12.12 41.8 ± 18.25
a 31.52 ± 13.75b, f 13.87 ± 8.81g 9.4 ± 5.3d, e
S100A12 (ng/ml) 16.32 ± 11.92 22.89 ± 15.20 176.69 ± 70.53a 193.04 ± 62.56b 198.13 ± 71.45c 176.19 ± 78.43d
S100A12N (pg/
mg)




3,805.61 ± 1,296.3b 3,593.58 ± 1,309.83c 3,474.96 ± 1,254.31d
Data are presented as mean ± SD, unless otherwise noted. PaO2, arterial oxygen tension; PaCO2, arterial carbon dioxide tension; FiO2, inspiratory oxygen fraction;
sRAGEN, sRAGE normalized for total protein amount; S100A12N, S100A12 normalized for total protein amount.
aP < 0.001 after CPB versus before surgery; bP <
0.001 1 hour after surgery versus before surgery; cP ≤ 0.05 12 hours after surgery versus before surgery; dP ≤ 0.002 24 hours after surgery versus before surgery;
eP < 0.001 24 hours after surgery versus after CPB; fP = 0.001 1 hour after surgery versus after CPB; gP < 0 .001 12 hours after surgery versus after CPB.
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P = 0.009); however, none of them was associated with
the ratio within 24 hours after surgery.
Likewise, elevated sRAGEN and S100A12N levels were
correlated with longer MV time (Figure 5A and 5B;
sRAGEN: r = 0.405; P = 0.002; S100A12N: r = 0.322; P =
0.014), surgical ICU LOS (Figure 5C and 5D; sRAGEN: r
= 0.421; P = 0.001; S100A12N: r = 0.365; P = 0.005) and
hospital LOS (Figure 5E and 5F; sRAGEN: r = 0.329; P =
0.012; S100A12N: r = 0.471; P = 0.001).
Discussion
In this prospective pilot study of the kinetics of plasma
sRAGE and S100A12 levels in infants and young chil-















































































































































































































Figure 2 Perioperative courses over time of plasma sRAGE and S100A12 levels in the acute lung injury (ALI) and non-ALI groups. Data
are expressed as mean ± standard error of the mean. *P < 0.01.
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that plasma concentrations of sRAGE and S100A12
remarkably increased immediately after CPB. The ele-
vated levels were correlated with the severity of ALI and
clinical outcomes of cardiac surgery with CPB and
plasma sRAGE was a reliable early predictor for the
occurrence of ALI after cardiac surgery.
Uniquely, RAGE is expressed at remarkably high basal
levels in lung tissues [9,11,12], suggesting that it holds
important functions in both pulmonary physiology and
numerous pathologic states [9,12]. The normal values of
sRAGE were reported to range from 500 to 1,250 pg/ml
in healthy volunteers [20,21,24,25]. In addition, no signif-
icant difference was found in normal plasma sRAGE
levels among various ages and in baseline levels with
respect to the cause of lung injury, such as aspiration
pneumonia, and to coexisting conditions, such as dia-
betes, end-stage renal disease, essential hypertension, or
other vascular diseases [13]. Previous studies provided
supportive evidence that the primary source of plasma
sRAGE in ALI/ARDS patients was alveolar type I cells
[11-13,24], and sRAGE served as a marker of alveolar
epithelial injury [15,16,24]. As expected, in the current
study, we found that the plasma levels of sRAGE were
significantly higher in the ALI group than in the non-ALI
group immediately after CPB. After adjusting the ALI-
related variants, sRAGE remained as an independent risk
factor for ALI development. Furthermore, we found the
sRAGE levels were related with the impaired lung func-
tion, such as lower PaO2/FiO2 ratio and higher radio-
graphic LIS. These findings suggested that plasma
sRAGE levels may serve as a reliable quantitative predic-
tor for the development of post-CPB ALI in infants and
young children. Because plasma was diluted during CPB,
the normalized plasma sRAGE and S100A12 concentra-
tions were used to define the cut-off values (sRAGE, 54
pg/mg; S100A12, 4,326.5 pg/mg) in our study. Neverthe-
less, the cut-off value should be used with caution to
diagnose ALI in a clinical setting, because the defined
abnormal sRAGE or S100A12 levels were unequal among
different studies in different patients [20,21,24,25].
Unfortunately, to date, only a few studies exist on sRAGE
and S100A12, which were always based on small number
of patients. Hence, a larger-cohort validation study is
needed to verify these results in future.
Previous studies have shown that the elevated circula-
tion levels of sRAGE after onset of ALI/ARDS soon
decreased to lower levels [13,14,17,18]. Interestingly, we
found similar kinetics of plasma sRAGE during CPB in
children, to those in adult patients receiving coronary
artery bypass grafting [20]. One possible explanation for
this decrement is the reoxygenation resulting from
reperfusion of the lung after CPB, because Lizotte et al.
[26] reported that hyperoxic exposures lead to a loss of
sRAGE in the neonatal rat lung. In addition, a great
number of activated neutrophils during extracorporeal
circulation may explain the decreasing sRAGE levels
[27]. sRAGE is known to have multiple protease-sensi-
tive sites, so it might be degraded by neutrophil-derived
proteolytic enzymes [28].
Infiltration of activated neutrophils is an important
hallmark of ALI [29]; therefore more neutrophils in ALI
may account for the high levels of S100A12 in the ALI
group. Although neutrophils and their secretory pro-
ducts play important roles in the pulmonary inflamma-
tion, such as ALI, they are a rather unspecific surrogate
for lung-tissue injury [29-31], which may contribute to
the disassociation of plasma levels of S100A12 with the
occurrence and the severity of post-CPB ALI in the
logistic analysis and the multiple linear regression
analysis.
In addition, the present study found that both plasma
levels of sRAGE and S100A12 immediately after CPB were
positively correlated with the duration of MV, surgical
ICU LOS, and hospital LOS, and that sRAGE showed an
independent association with the PaO2/FiO2 ratio on the
second day. Although speculative, the following reasons
might explain these correlations. In ALI/ARDS patients,
Mauri et al. [15] reported that the first-day plasma sRAGE
levels were correlated with the release of CRP and pen-
traxin 3 (PTX3) in the circulation [15], which promoted
the coagulation/fibrinolysis dysfunction and organ failures
[15,32]. RAGE interacts with leukocyte Mac-1 integrin,
monocyte chemoattractant protein-1, and CD11c/CD18 to





Figure 3 Receiver operating characteristic curves displaying
the ability of plasma levels of sRAGEN and S100A12N to
predict the occurrence of ALI. The AUCs of sRAGEN and S100A12N
for ALI were 0.775 (95% CI, 0.626 to 0.924) and 0.714 (95% CI, 0.539
to 0.889), respectively. ALI, acute lung injury; AUC, area under the
curve.
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of leukocytes to an inflammation site is additionally aug-
mented by interaction with RAGE ligands such as
S100A12 [10,14,18,32]. Furthermore, interaction of RAGE
and S100A12 causes production of proinflammatory cyto-
kines including TNF-a, IL-6, and IL-8 [12,21], which
induced increased lung cell damage and vascular perme-
ability [34,35]. Taken together, RAGE and S100A12 con-
tribute to more severe and prolonged inflammation in the
lung and damage of the alveolar capillary barrier with
increased lung water content and impaired oxygenation,
resulting in longer MV support and more critical care in
the SICU after cardiac surgery. There was no doubt that
the S100A12-RAGE axis played an important role in the
development of ALI after cardiac surgery with CPB.
Because several single nuclear polymorphisms of the
RAGE gene were recently found to affect the expression of
sRAGE and associate with lung function in pathologic
states [36-38], it should be emphasized that genetic varia-
tion of RAGE must be considered in further studies.
Limitations of the present study should be acknowl-
edged. Although the kinetics of plasma sRAGE levels in
this study is consistent with that in a published study
[20], our findings were based on a small number of
patients in a single center, which might limit the applica-
tion of these findings to other institutions. Furthermore,
we enrolled the patients undergoing surgery for CHD in
the absence of relevant comorbidities and particularly of
known lung disease. Therefore, we are not sure whether
the sRAGE and S100A12 changes would be the same in
the presence of previous lung diseases. Because children
often have pneumonias before cardiac operations, future
studies must confirm this.
Interestingly, Jabaudon et al. [13] reported that
sRAGE levels in ALI/ARDS were not influenced by the
presence of RAGE-related diseases such as sepsis, dia-
betes mellitus, end-stage renal disease, coronary artery



































































































r = - 0.56
p < 0.001
p < 0.01 p <0.01
Figure 4 Plasma sRAGEN and S100A12N levels immediately after CPB reflecting the PaO2/FiO2 ratio (A-D) and radiographic LIS (E, F).
LIS, lung-injury score.
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Third, the traditional inflammatory cytokines were
not measured in this study. However, none of them
was a specific biomarker for post-CPB ALI, although
they were found to change perioperatively. In addition,
in vitro study showed that the induction of S100A12
was more prominent than other cytokines, such as IL-
8 [14], suggesting that the S100A12-RAGE axis may be
more important in the CPB-induced inflammatory
response.
Conclusions
We found that plasma sRAGE acts as a reliable early
biomarker of ALI after cardiac surgery with CPB in
infants and young children. The plasma levels of sRAGE
and S100A12 are associated with lung function and clin-
ical outcomes after CPB. These data may indicate that
RAGE is a mediator of lung injury in patients after car-
diac surgery and not merely a maker of disease. Insight
into the role of the ligand-RAGE axis in the post-cardiac
surgery inflammatory response holds the potential for
better understanding of ALI induced by CPB.
Key messages
• Early identification of the occurrence of acute
lung injury (ALI) would facilitate efficient thera-
peutic decision making in infants and young chil-
dren after cardiac surgery with cardiopulmonary
bypass (CPB).
• Plasma sRAGE and S100A12 levels increased after
CPB, and the plasma levels of sRAGE immediately
after CPB showed high predictive values for the
development of ALI in infants and young children
after cardiac surgery necessitating CPB.
• Increased sRAGE and S100A12 levels immediately
after CPB significantly reflected the severity of ALI
and are correlated with longer mechanical ventila-





































































































































Figure 5 Scatterplot displaying the relation between plasma sRAGEN and S100A12N levels immediately after CPB and the clinical
outcomes. The mechanical ventilation time (A, B), the ICU LOS (C, D), and the hospital LOS (E, F) are shown.
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• Further studies are required to confirm the value
of sRAGE in predicting ALI after cardiac surgery
with CPB in a larger population.
Additional material
Additional file 1: Standard protocols for anesthesia,
cardiopulmonary bypass, and weaning from mechanical ventilation.
Additional file 1 is the standard protocols for anesthesia,
cardiopulmonary bypass, and weaning from mechanical ventilation,
which were used in all patients.
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